ORLANDO, Fla.--(BUSINESS WIRE)--IntegraGen, a leading player in the development and marketing of molecular diagnostic testing in autism and oncology, today announced the results of a study that reports the ability to predict the risk of autism spectrum disorder (ASD) in children with signs of developmental delay or autism. The research, presented during the American Academy of Child & Adolescent Psychiatry meeting in Orlando, Florida, reports on the identification of over 1,500 genetic variants shown to be associated with autism. The present study, which included nearly 2,500 children diagnosed with autism and 3,500 controls, builds on research the company previously presented that identified single-nucleotide polymorphisms (SNPs) which predict the risk of autism in children who have an older sibling diagnosed with ASD.
Help employers find you! Check out all the jobs and post your resume.